Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers explored drug repurposing as a potential strategy for treating psoriasis and identified Pioglitazone, Trimipramine, and Dimetindene as promising candidates for this indication, based on molecular docking and predictive algorithms.

This study found that FDA-cleared devices for preparing platelet-rich plasma showed inconsistent product quality, with variable platelet counts and inadequate quality control performance, suggesting clinical improvement may not rely on platelet concentration.

This study identified five FDA-approved drugs—cepharantine, clofazimine, metergoline, imatinib, and efloxate—as potential candidates for repurposing to interfere with viral entry in COVID-19 treatment.

This study reported that FDG PET/CT imaging provided additional information that significantly impacted the treatment and prognosis in seven out of ten canine cancer patients, suggesting its potential in veterinary oncology.

This study analyzed the FDA Adverse Event Reporting System and found distinct safety signals and adverse event patterns among α1-blockers, 5α-reductase inhibitors, and tadalafil used in treating benign prostatic hyperplasia, emphasizing known risks and identifying potential new ones that require further study.

This study examined the FDA Adverse Event Reporting System database and found significant associations between low-dose oral minoxidil use and adverse events like pericardial effusion, highlighting the need for caution and recommending the use of the lowest effective dose until more safety data are available.

This study investigated medications potentially linked to male-factor infertility using the FDA Adverse Event Reporting System and found that finasteride, testosterone, valproate, and other drugs showed significant disproportionate reporting of infertility cases, highlighting a potential under-reporting issue to regulatory bodies.

This study used computational methods to identify pranlukast and mirabegron as promising candidates for repurposing against diabetes due to their good binding interactions with the DPP-IV target.

This study identified five FDA-approved drugs, including cepharantine and clofazimine, as potential COVID-19 therapies through in silico and in vitro screening targeting viral entry mechanisms.

This study suggests that statins may be linked to various ovary and uterus related adverse events, highlighting the need for monitoring in clinical practice.

This article discusses the regulatory gap in updating labeling responsibilities for generic drugs and argues for the FDA to use negotiated rulemaking to develop more effective drug regulations, but provides no new empirical results.

This study highlights the approval of orforglipron under the FDA's National Priority Voucher program, emphasizing its significance as a convenient oral treatment option with beneficial effects on glycemic and lipid profiles for diabetes and obesity management.

This study analyzed data from the FDA Adverse Event Reporting System and found that enfortumab vedotin, used for urothelial carcinoma, is linked to various cutaneous adverse events, including severe reactions like Stevens–Johnson syndrome, typically occurring early in treatment and predominantly affecting elderly male patients.

This study investigated paternal drug exposure using FDA data and identified significant associations with reproductive health risks, including congenital anomalies linked to immunosuppressive drugs, and emphasized specific risk combinations like biologics and abortion, diazepam and small for date baby, and finasteride and cryptorchidism.

This article examines how the Dietary Supplement Health and Education Act of 1994 allows ineffective herbal remedies for hair loss to remain on the market, potentially misleading consumers, and suggests possible solutions.

This research overview discusses Post-Finasteride Syndrome, presenting data from an FDA database, but it does not report any new clinical findings.

This study mapped the safety profile of EGFR-TKIs by analyzing FDA adverse event reports, highlighting unexpected reactions like intestinal obstruction and hypokalaemia with gefitinib and erlotinib.

This study identified common and previously unlisted adverse events associated with four anti-CGRP monoclonal antibodies for migraine prevention, highlighting a varied safety profile post-marketing.

This article reviews 27 small-molecule drugs approved by the FDA in 2024, noting that among them, eight "first-in-class" drugs with breakthrough therapy status show distinct mechanisms and substantial efficacy improvements in various conditions like cancer and chronic diseases.

This review discusses the use of platelet-rich plasma for alopecia treatment and notes a lack of data on the consistency of FDA-approved PRP devices in clinical settings.

This study introduced and validated new spectrophotometric methods to simultaneously determine finasteride and tadalafil in Entadfi™ capsules with high sensitivity and without interference from excipients.

This study analyzed pexidartinib-associated adverse events from FDA data and reported common events such as hepatic issues and systemic reactions. It highlighted sex-specific susceptibilities and reinforced the need for risk mitigation and long-term monitoring in tenosynovial giant cell tumor management.

This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.

This review discusses advancements in skin microphysiological systems, such as 3D bioprinting, skin organoids, and skin-on-a-chip, and their effectiveness in emulating human skin functions for research and preclinical applications, highlighting the potential for replacing animal testing with these innovative technologies.

This study found that testosterone and finasteride were significantly associated with reports of male-factor infertility based on FDA pharmacovigilance data from 2010 to 2020.

In this study, data from the FAERS database indicated varied associations between certain medications and obstructive sleep apnea, with some biologics associated with a decreased risk of developing the condition.

This study analyzed 3,295 cases from the FDA Adverse Event Reporting System to describe demographics and reporting trends of post-finasteride syndrome, finding that most reports came from patients rather than health professionals.

This study reports that Elvitegravir, a drug currently approved for other uses, shows potential as a neuro- and mitoprotective agent by attenuating mitochondrial damage caused by NMDA receptors in primary mouse cortical neurons.

This study analyzed post-marketing data from the U.S. FDA Adverse Event Reporting System and identified both known and new safety concerns for Avacopan, an anti-neutrophil cytoplasmic antibodies-associated vasculitis treatment, emphasizing the need for monitoring during early treatment stages.